Innate Pharma SA IPHA 深 滬
交易中 06-25 10:16:32 美东时间
1.90
0.000
0.00%
華盛通- 最 高1.85
- 今 開1.85
- 成交量 224股
- 最 低 1.85
- 昨 收 1.90
- 總市值 1.78亿
- 52周最高 2.63
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.17
- 委 比 -55.46%
- 總股本 9390.33万
- 歷史最高 11.95
- 量 比 0.38
- 振 幅 0.00%
- 歷史最低 1.17
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Alpha Compute (NASDAQ:ALP) shares increased by 71.3% to $0.46 during T...
05-14 20:05
Innate Pharma Advances Lacutamab Phase 3 Trial And IPH4502 ADC Amid €25.4M Cash Runway Through Q3 2026
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma
05-13 13:31
Innate Pharma To Present Phase 2 MATISSE Prospectus Data On IPH5201 Combo In Resectable Lung Cancer At AACR 2026
Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and chemotherapy in resectable
04-18 03:01
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $5 price target.
04-08 01:45
Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
Innate Pharma FY EPS $(0.64) Beats $(0.65) Estimate, Sales $10.483M Beat $7.230M Estimate
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 1.69 percent increase over losses of $(0.65) per share from the
03-26 14:14
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8
BTIG analyst Jeet Mukherjee assumes Innate Pharma (NASDAQ:IPHA) with a Buy rating and announces Price Target of $8.
03-12 18:58
Innate Pharma to Join Leerink Partners Global Healthcare Conference in Miami
Innate Pharma to Join Leerink Partners Global Healthcare Conference in Miami Innate Pharma SA will participate in the Leerink Partners Global Healthcare Conference 2026, held in Miami, Florida, from March 8-11, 2026. The company’s executive team will join a fireside chat on March 9, 2026, at 3:40 PM
02-18 14:00
